Compare ATR & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATR | JAZZ |
|---|---|---|
| Founded | 1992 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 10.4B |
| IPO Year | 1995 | 2007 |
| Metric | ATR | JAZZ |
|---|---|---|
| Price | $143.92 | $189.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | $167.50 | ★ $211.25 |
| AVG Volume (30 Days) | 591.3K | ★ 940.2K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | ★ 6.51 | N/A |
| EPS | ★ 5.89 | N/A |
| Revenue | ★ $3,777,181,000.00 | $1,618,693,000.00 |
| Revenue This Year | $5.29 | $7.60 |
| Revenue Next Year | $4.98 | $8.34 |
| P/E Ratio | $24.11 | ★ N/A |
| Revenue Growth | ★ 5.42 | N/A |
| 52 Week Low | $103.23 | $95.49 |
| 52 Week High | $164.28 | $198.00 |
| Indicator | ATR | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 67.20 | 70.80 |
| Support Level | $135.99 | $159.78 |
| Resistance Level | $163.43 | N/A |
| Average True Range (ATR) | 3.08 | 5.21 |
| MACD | -0.01 | 2.75 |
| Stochastic Oscillator | 79.91 | 77.33 |
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. Its sales are primarily from Europe (49% of sales) and the United States (28%), with China contributing 5% and other countries contributing 17%. It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.